

 $401\,\mathrm{WEST\,MAIN\,ST.}, \mathrm{SUITE\,222 \cdot LEXINGTON}, \mathrm{KY\,40507 \cdot 859-759-4081 \cdot CONTACTUS@RMTCNET.COM \cdot RMTCNET.COM \cdot RMTCNET.COM$

MEMORANDUM

TO: Association of Racing Commissioners International

FROM: RMTC Board of Directors

DATE: October 28, 2023

RE: Proposed Classification

The RMTC is submitting a recommendation for a penalty classification for Troparil.

Troparil

The RMTC has received intelligence that Troparil is a potential emerging threat in the US.

The stimulant Troparil is a phenyltropane-based dopamine reuptake inhibitor, with a higher potency and longer duration of action than cocaine. Troparil has similar effects to cocaine in animal studies, but recreational use of this compound to date has proven extremely rare.

The legal status of Troparil is unclear but can reasonably be considered a controlled substance analog of cocaine on the grounds of its related chemical structure. The Federal Analogue Act, a section of the United States Controlled Substances Act, allows any chemical "substantially similar" to a controlled substance listed in Schedule I or II to be treated as if it were listed in Schedule I.

Troparil does not have FDA approval for use in any species.

Troparil is not listed in ARCI's Uniform Classification of Foreign Substances, so pursuant to ARCI Model Rules, this substance would be assigned 1A by default.

The FDA advised the RMTC (in response to its inquiry on other substances) that the possession of a non-FDA approved drug is not permitted, nor is the compounding of a non-FDA approved substance.

As it lacks FDA approval, it would be classified as a Banned (S0) Substances by HISA's Anti-Doping and Medication Control regulations.

Based on intelligence received that Troparil is a potential emerging threat in the US, RMTC's Board of Directors voted unanimously, October 2, 2023, to recommend a 1/A Classification.

Recommendation: 1A